Prostaglandin H synthase Inhibitors
1 drugsAbout Prostaglandin H synthase
Prostaglandin H synthase, or cyclooxygenase (COX), is an enzyme involved in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. These signaling molecules mediate inflammation, pain, and fever.
Prostaglandin H synthase is a therapeutic target for pain management due to its role in inflammatory pathways. Currently, there is no genetic evidence directly linking Prostaglandin H synthase to specific diseases.
ILEVRO is the only FDA-approved drug targeting Prostaglandin H synthase, developed by HARROW EYE as a small molecule for pain relief. It was first approved in 2012.
Top Prostaglandin H synthase Drugs
HARROW EYE is the only company with an approved drug targeting Prostaglandin H synthase.
Low competition suggests an opportunity for new entrants, but also indicates potential market challenges.
Prostaglandin H synthase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Prostaglandin H synthase, using small molecule modality.
Exploring alternative modalities like antibodies or biologics could provide differentiation.
Prostaglandin H synthase Clinical Trials 28 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Prostaglandin H synthase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 5 | 4 | 1 | 0 | 80% |
| Phase 3 | 7 | 6 | 1 | 0 | 86% |
| Phase 4 | 16 | 13 | 1 | 2 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Prostaglandin H synthase Drug Approval Timeline (2012 - 2012)
The first and only drug, ILEVRO, was approved in 2012.
The lack of recent approvals suggests market saturation or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 20 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Prostaglandin H synthase. A trial counts if an approved drug acting on Prostaglandin H synthase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.